An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.

OBJECTIVE Primary ovarian cancer cells obtained from fresh tumor have many advantages over established cell lines. Therefore, a procedure for the specific and efficient purification of such neoplastic cells is critical. We report an effective immunomagnetic method for the isolation of tumor cells from the ascitic fluid of patients diagnosed with ovarian adenocarcinoma. METHODS This procedure incorporates the use of monoclonal antibody (mAb) CC49, which recognizes the tumor-associated glycoprotein 72 (TAG-72). TAG-72 is highly expressed on ovarian tumor cell surfaces with little or no reactivity with normal tissues. Also used in this protocol are immunomagnetic beads, which bind to the CC49 mAb via a secondary antibody. When ovarian cancer cells adhere to the magnetic beads, a magnetic field is used to separate the tumor cells from all other cellular components. RESULTS Using ascitic fluid from five patients, we found that preparations before purification contained between 38 and 52% neoplastic cells. Using our method, we produced preparations that were between 63 and 96% pure for cancer cells, thus obtaining an average increase in tumor cell enrichment of 86%. CONCLUSION We, therefore, believe this method is preferable for producing high yields of pure ovarian neoplastic cells. We are now employing this technique in our laboratory to provide a stringent and pure template for our studies on gene transfer to primary ovarian cancer cells.

[1]  C. Richter,et al.  Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. , 2000, Human gene therapy.

[2]  D. Curiel,et al.  An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  D. Curiel,et al.  Pro‐apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer , 2000, The journal of gene medicine.

[4]  Y. Shima,et al.  Isolation and characterization of human multiple myeloma cell enriched populations. , 2000, Journal of immunological methods.

[5]  D. Curiel,et al.  Detection of Coxsackie–Adenovirus Receptor (CAR) Immunoreactivity in Ovarian Tumors of Epithelial Derivation , 1999 .

[6]  I. Eltoum,et al.  Epithelioid variant of malignant peripheral nerve sheath tumor (malignant schwannoma) of the urinary bladder. , 1999, Annals of diagnostic pathology.

[7]  E. Partridge,et al.  Epithelial ovarian cancer: Prevention, diagnosis, and treatment , 1999, CA: a cancer journal for clinicians.

[8]  I. Safarik,et al.  Use of magnetic techniques for the isolation of cells. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[9]  D. Kerr,et al.  Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells , 1998, Gene Therapy.

[10]  M. Labopin,et al.  Comparison of CD34+ bone marrow cells purified by immunomagnetic and immunoadsorption cell separation techniques , 1998, Bone Marrow Transplantation.

[11]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.

[12]  W. Hsu,et al.  Immunomagnetic Isolation of Islets from the Rat Pancreas , 1997, Biotechnology progress.

[13]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  R. Bast,et al.  Transforming growth factor‐beta inhibits proliferation of human ovarian cancer cells obtained from ascites , 1994, Cancer.

[15]  H. Hirte,et al.  A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma , 1992, Gynecologic oncology.

[16]  L. Durrant A rapid method for separating tumour infiltrating cells and tumour cells from colorectal tumours. , 1992, Journal of immunological methods.

[17]  H. Yamaue,et al.  Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. , 1991, European journal of cancer.

[18]  J. Wharton,et al.  Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. , 1991, Cancer research.

[19]  H. Yamaue Chemosensitivity testing with highly purified fresh human tumor cells with the MTT assay , 1991 .

[20]  A. Thor,et al.  Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. , 1989, Acta cytologica.

[21]  J. Schlom,et al.  Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. , 1988, Cancer research.

[22]  M. Broggini,et al.  Human ovarian tumors in primary culture: Growth, characterization and initial evaluation of the response to cis platinum treatment in vitro , 1988, International journal of cancer.

[23]  L. Mansi,et al.  A prospective imaging study of 131I‐B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report , 1988, Nuclear medicine communications.

[24]  J. Kemshead,et al.  Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. , 1986, British Journal of Cancer.

[25]  R. W. Baldwin,et al.  Association of antigen expression and DNA ploidy in human colorectal tumors. , 1986, Cancer research.

[26]  A. Hamburger,et al.  Percoll density gradient separation of cells from human malignant effusions. , 1985, British Journal of Cancer.

[27]  J. Lechner,et al.  Cell Separation by Biological Methods , 1984 .

[28]  II Pretlow,et al.  Cell Separation: Methods and Selected Applications , 1983 .

[29]  W. Mackillop,et al.  Measurement of self-renewal in culture of clonogenic cells from human ovarian carcinoma. , 1981, British Journal of Cancer.

[30]  R. G. Ham,et al.  Survival and Growth Requirements of Nontransformed Cells , 1981 .